Detalles de la búsqueda
1.
Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023.
Clin Infect Dis
; 78(4): 1056-1064, 2024 Apr 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-38051664
2.
Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants.
J Infect Dis
; 228(3): 235-244, 2023 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36883903
3.
Vaccine Effectiveness Against Influenza A(H3N2)-Associated Hospitalized Illness: United States, 2022.
Clin Infect Dis
; 76(6): 1030-1037, 2023 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36327388
4.
Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022.
Clin Infect Dis
; 77(4): 547-557, 2023 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-37255285
5.
Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023.
MMWR Morb Mortal Wkly Rep
; 72(17): 463-468, 2023 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37104244
6.
Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged ≥60 Years - IVY Network, 20 U.S. States, February 2022-May 2023.
MMWR Morb Mortal Wkly Rep
; 72(40): 1083-1088, 2023 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37796753
7.
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
MMWR Morb Mortal Wkly Rep
; 71(5152): 1625-1630, 2022 Dec 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-36580424
8.
Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
MMWR Morb Mortal Wkly Rep
; 71(42): 1327-1334, 2022 Oct 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36264830
9.
SARS-CoV-2 shedding and evolution in patients who were immunocompromised during the omicron period: a multicentre, prospective analysis.
Lancet Microbe
; 5(3): e235-e246, 2024 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38286131
10.
Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults.
JAMA Netw Open
; 7(4): e244954, 2024 Apr 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38573635
11.
SARS-CoV-2 shedding and evolution in immunocompromised hosts during the Omicron period: a multicenter prospective analysis.
medRxiv
; 2023 Aug 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-37662226
12.
Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022.
Vaccine
; 41(29): 4249-4256, 2023 06 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37301704
Resultados
1 -
12
de 12
1
Próxima >
>>